EP2739613A4 - Flavonoid compounds - Google Patents

Flavonoid compounds

Info

Publication number
EP2739613A4
EP2739613A4 EP12821887.2A EP12821887A EP2739613A4 EP 2739613 A4 EP2739613 A4 EP 2739613A4 EP 12821887 A EP12821887 A EP 12821887A EP 2739613 A4 EP2739613 A4 EP 2739613A4
Authority
EP
European Patent Office
Prior art keywords
flavonoid compounds
flavonoid
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12821887.2A
Other languages
German (de)
French (fr)
Other versions
EP2739613A2 (en
Inventor
Cyrus K Becker
George F Schreiner
Sundeep Dugar
Dinesh Mahajan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epirium Bio Inc
Original Assignee
Cardero Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardero Therapeutics Inc filed Critical Cardero Therapeutics Inc
Publication of EP2739613A2 publication Critical patent/EP2739613A2/en
Publication of EP2739613A4 publication Critical patent/EP2739613A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP12821887.2A 2011-08-05 2012-08-06 Flavonoid compounds Withdrawn EP2739613A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515631P 2011-08-05 2011-08-05
PCT/US2012/049767 WO2013022846A2 (en) 2011-08-05 2012-08-06 Flavonoid compounds

Publications (2)

Publication Number Publication Date
EP2739613A2 EP2739613A2 (en) 2014-06-11
EP2739613A4 true EP2739613A4 (en) 2015-01-07

Family

ID=47669187

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12821887.2A Withdrawn EP2739613A4 (en) 2011-08-05 2012-08-06 Flavonoid compounds

Country Status (5)

Country Link
US (1) US9187448B2 (en)
EP (1) EP2739613A4 (en)
JP (1) JP2014521702A (en)
CN (1) CN103987704A (en)
WO (1) WO2013022846A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170430A1 (en) 2011-06-06 2012-12-13 Cardero Therapeutics, Inc. Methods and compositions for treatment of mitochondrial toxicity
US20140179774A1 (en) * 2012-12-26 2014-06-26 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases
EP2943479B1 (en) 2013-01-11 2020-04-15 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
CN112724114A (en) * 2013-04-04 2021-04-30 斯法尔制药私人有限公司 Epicatechin and related polyphenols
EP3795578A3 (en) 2014-07-23 2021-05-26 Sphaera Pharma Pvt. Ltd. Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
CN104311523A (en) * 2014-09-30 2015-01-28 浙江大学 Method for selectively preparing 3',4'-diester-based catechin
CN104292201B (en) * 2014-09-30 2017-05-10 浙江大学 Method for preparing 3-ester group catechin
CN104311524B (en) * 2014-09-30 2016-12-07 浙江大学 3 ', 4 ', 5,7-tetra-ester group catechin method for selective production and product
CN104311542A (en) * 2014-09-30 2015-01-28 浙江大学 Selective preparation method and product of 3-tetrahydropyrane-based catechin
CN104910119B (en) * 2015-04-30 2017-08-15 天津科技大学 One class cumarin substitution flavone derivative and its preparation method and application
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
CN109415400A (en) * 2016-06-21 2019-03-01 斯法尔制药私人有限公司 The purposes of (+) epicatechin and the like
CA3029450C (en) 2016-06-27 2021-07-13 The General Hospital Corp Dba Massachusetts General Hospital Stimulating platelet generation by activating mitochondrial biogenesis
BR112020024695A2 (en) * 2018-06-05 2021-03-02 Flagship Pioneering Innovations V, Inc active agents and methods of using these for the treatment of metabolic disorders and non-alcoholic fatty liver disease
CN113227067A (en) 2018-10-24 2021-08-06 埃皮里姆生物股份有限公司 Co-crystals comprising epicatechin and a carboxy-N-heterocyclic co-crystal former
CN111773232B (en) * 2020-06-29 2023-07-25 烟台大学 Application of new flavonoid compound Hip A
JP7352596B2 (en) * 2021-06-01 2023-09-28 花王株式会社 Method for producing catechin conjugate
CN115385885A (en) * 2022-05-05 2022-11-25 深圳海创生物科技有限公司 Blueberry polyphenol, composition and application of blueberry polyphenol in preparation of medicines or foods with blood fat reducing and/or weight losing effects
WO2024036223A1 (en) 2022-08-10 2024-02-15 Epirium Bio Inc. Epicatechin inhibiting atp hydrolysis
WO2024036225A1 (en) 2022-08-10 2024-02-15 Epirium Bio Inc. Epicatechin for inhibiting glutamate toxicity
CN115504970B (en) * 2022-10-18 2023-04-18 黑龙江中医药大学 Flavonoid derivative for treating myocardial ischemia and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034976A1 (en) * 2003-09-12 2005-04-21 Mitsui Norin Co., Ltd Antimicrobial compositions and methods of use
JP2006249056A (en) * 2005-03-07 2006-09-21 Mitsui Norin Co Ltd Uterine cancer inhibitor
WO2010121232A1 (en) * 2009-04-17 2010-10-21 Cardero Therapeutics, Inc. Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435166B (en) * 2004-11-04 2009-07-08 Univ Tsukuba High molecular weight polphenols extracted from fermented tea and a method of manufacturing a medicament for the prevention and treatment of diabetes
WO2008011173A2 (en) * 2006-07-21 2008-01-24 Mars, Incorporated Improvement of arginase levels/activity
CN101947319B (en) * 2009-07-10 2015-09-09 杏辉天力（杭州）药业有限公司 Treat and prevent patient because of the medical composition of the discomfort caused by myocardial ischemia
CN101984965A (en) * 2010-11-18 2011-03-16 安徽农业大学 Application of epicatechin gallate and derivatives thereof for treating or preventing myocardial infarction and other ischemic heart diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034976A1 (en) * 2003-09-12 2005-04-21 Mitsui Norin Co., Ltd Antimicrobial compositions and methods of use
JP2006249056A (en) * 2005-03-07 2006-09-21 Mitsui Norin Co Ltd Uterine cancer inhibitor
WO2010121232A1 (en) * 2009-04-17 2010-10-21 Cardero Therapeutics, Inc. Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BASAK A ET AL: "Studies on the porcine liver esterase-catalyzed hydrolysis of pentaacetyl catechin and epicatechin: Application to the synthesis of novel dimers and trimers", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 17, 1 September 2008 (2008-09-01), pages 4900 - 4903, XP024100126, ISSN: 0960-894X, [retrieved on 20080717], DOI: 10.1016/J.BMCL.2008.07.058 *
T.P.T. CUSHNIE ET AL: "Investigation of the antibacterial activity of 3- O -octanoyl-(-)-epicatechin", JOURNAL OF APPLIED MICROBIOLOGY, vol. 105, no. 5, 1 November 2008 (2008-11-01), pages 1461 - 1469, XP055154808, ISSN: 1364-5072, DOI: 10.1111/j.1365-2672.2008.03881.x *

Also Published As

Publication number Publication date
JP2014521702A (en) 2014-08-28
US9187448B2 (en) 2015-11-17
WO2013022846A3 (en) 2013-10-24
CN103987704A (en) 2014-08-13
US20140256741A1 (en) 2014-09-11
EP2739613A2 (en) 2014-06-11
WO2013022846A2 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
IL286152A (en) Substituted imidazopyridinyl-aminopyridine compounds
EP2739613A4 (en) Flavonoid compounds
IL233154A0 (en) Compounds
GB201109763D0 (en) Compounds
GB201106395D0 (en) Compounds
ZA201306857B (en) Mesogen-containing compounds
SG10201601802YA (en) Dispiropyrrolidine derivatives
EP2684886A4 (en) Chromene compound
IL247636A0 (en) Heteroarylpiperidine derivatives
GB201122139D0 (en) Compounds
EP2725017A4 (en) Chromene compound
GB201107197D0 (en) Compounds
IL231950B (en) Aryl-quinoline derivatives
EP2721029A4 (en) Imidazopyridin-2-one derivatives
EP2669278A4 (en) Chromene compound
EP2669277A4 (en) Chromene compound
GB201110938D0 (en) Compounds
HK1191326A1 (en) Azaspirodecanone compounds
SI2766342T1 (en) Phenyl-guanidine derivatives
GB201105659D0 (en) Compounds
IL228486A0 (en) 3-ureidoisoquinolin-8-yl derivatives
GB201118613D0 (en) Compounds
GB201120805D0 (en) Compounds
GB201119745D0 (en) Compounds
GB201119703D0 (en) Compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140327

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20141204

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/353 20060101ALI20141128BHEP

Ipc: A61P 9/00 20060101ALI20141128BHEP

Ipc: C07D 311/62 20060101AFI20141128BHEP

Ipc: A61P 25/00 20060101ALI20141128BHEP

Ipc: A61P 3/00 20060101ALI20141128BHEP

17Q First examination report despatched

Effective date: 20160119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160531